REMS: The Next Pharmaceutical Enforcement Priority?

9 Pages Posted: 28 Mar 2014

See all articles by Darren S. Tucker

Darren S. Tucker

Vinson & Elkins LLP

Gregory Wells

Vinson & Elkins LLP

Margaret Sheer

Bingham McCutchen, LLP

Date Written: 2014


Under the Food and Drug Administration Amendments Act of 2007, the FDA can require the use of risk evaluation and mitigation strategies (REMS) over and above professional labeling, to ensure that a drug’s benefits outweigh its risks. The FTC and the generic drug industry have raised concerns that branded drug companies are using REMS-mandated distribution restrictions to inappropriately limit access to product samples that generic drug developers need for bioequivalence testing, a predicate for FDA approval of generic drugs.

Though the FTC has not yet brought an enforcement action, the agency has identified REMS misuse as an enforcement priority, has opened several investigations, and has filed an amicus brief in private litigation explaining its concerns. For their part, generic drug companies have filed several antitrust claims against branded drug companies and raised their concerns with the FDA. Two district courts have permitted these claims to proceed, but the extent to which the antitrust laws require branded drug companies to provide generic firms access to product samples for REMS-restricted drugs remains unclear.

In this article, we discuss whether a refusal to supply a REMS-restricted drug to a generic drug developer is a form of exclusionary conduct under Section 2 of the Sherman Act, as well as potential justifications for a branded company’s refusal to deal. Given the FTC’s interest in this issue, we also address whether a refusal to provide REMS-restricted product samples to a generic drug company could raise concerns under Section 5 of the FTC Act.

Keywords: REMS, FTC, FDA, antitrust, competition, Sherman Act, FTC Act, refusal to deal, Trinko

JEL Classification: I18, K21, K23, L40, L41, L42, L43, L44, L49

Suggested Citation

Tucker, Darren S. and Wells, Gregory and Sheer, Margaret, REMS: The Next Pharmaceutical Enforcement Priority? (2014). Antitrust Magazine, Vol. 28, No. 2, 2014. Available at SSRN:

Darren S. Tucker (Contact Author)

Vinson & Elkins LLP ( email )

2200 Pennsylvania Ave NW
Washington, DC 20037
United States

Gregory Wells

Vinson & Elkins LLP ( email )

2200 Pennsylvania Ave., NW
Washington, DC 20037
United States

Margaret Sheer

Bingham McCutchen, LLP ( email )

2020 K Street NW
Washington, DC 20006
United States

Register to save articles to
your library


Paper statistics

Abstract Views
PlumX Metrics

Under construction: SSRN citations while be offline until July when we will launch a brand new and improved citations service, check here for more details.

For more information